Top Markets
Coin of the day
Acusphere, Inc. Acusphere, Inc.

Acusphere, Inc.

ACUS
Rank in Stocks #42813
Acusphere, Inc. is a pharmaceutical firm specializing in the creation and... Acusphere, Inc. is a pharmaceutical firm specializing in the creation and market launch of cardiovascular treatments. Its flagship product is Imagify (perflubutane polymer microspheres), a cardiovascular medication designed to assess myocardial perfusion and aid in the diagnosis of coronary artery disease. This drug is administered as an injectable suspension. Initially established as Polymers For Medicine, Inc., the organization rebranded as Acusphere, Inc. in March 2004. Founded in 1993, the company maintains its headquarters in Watertown, Massachusetts.
Share Price
$0.00001
Last synced: 2026-08-11
Market Cap
$49.00
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Acusphere, Inc. (ACUS)

Category

P/E ratio for Acusphere, Inc. (ACUS)
P/E ratio as of 2026 TTM: 0
According to Acusphere, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Acusphere, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.